Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Personalized neoantigen vaccine 2
- Development stage
- Preclinical
- Lead developer
- NeoCura
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intramuscular, Intranodal, Intravenous
01
Overview
Personalized neoantigen vaccine 2 is an investigational mRNA-based cancer vaccine developed by NeoCura for the treatment of multiple tumor types. As part of the NeoCura Ag-IND product line, it utilizes a one-to-one customized therapy approach tailored to the unique mutational profile of an individual patient's tumor. The vaccine is designed using NeoCura's proprietary AI-driven ALPINE platform and MATHLA deep learning model, which identify and select the most immunogenic neoantigen fragments from a patient's genomic sequencing data. These fragments are synthesized as coding mRNA sequences that, upon administration, stimulate the patient's immune system to recognize and mount a targeted T-cell response against tumor cells expressing those specific neoantigens. The candidate is currently in the IND-enabling phase of development.
- Other names
- NeoCura Ag-INDNeoCura Agpersonalized neoantigen vaccine
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on Personalized neoantigen vaccine 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Personalized neoantigen vaccine 2.